In light of this, preclinical data summarized in this review have clearly suggested that β3-AR is able to modulate the activity of different cells in the melanoma microenvironment and, consequently, its blockade exerts an important anti-tumor action by affecting multiple pro-tumor signaling pathways. This evidence concerns the gene ADRB3 and melanoma.